
Lymphatica Medtech
A minimally invasive implant and a discrete wearable device designed to re-establish the lymphatic circulation.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | €17.9m | Series B | |
Total Funding | 000k |
Related Content
Lymphatica Medtech is a clinical-stage medical device company focused on developing solutions for lymphatic diseases, specifically chronic lymphedema. The company is working on LymphoDrain™, an active implantable lymphatic bypass system designed to alleviate the symptoms of this condition.
The system consists of a magnetically controlled micropump and catheters that are implanted subcutaneously. This device works by draining the excess lymphatic fluid that accumulates in tissues, which is characteristic of lymphedema. The minimally invasive nature of the implant is a key feature of the proposed treatment.
Lymphatica Medtech's primary market is patients suffering from chronic lymphedema, a condition that can be genetic or occur as a result of other medical treatments, such as cancer therapy. The company's business model revolves around the research, development, and eventual commercialization of its medical devices. As a clinical-stage company, it is currently focused on securing regulatory approval and conducting clinical trials to validate the safety and efficacy of its technology. The company has successfully raised capital through multiple funding rounds to support these efforts.
Keywords: lymphedema, medical device, implantable pump, lymphatic system, vascular disease, chronic condition, minimally invasive, clinical-stage, micropump, catheters